Therefore, afatinib may be considered an alternative to osimertinib for first-line treatment of EGFR-positive NSCLC especially if medical cost is a concern or if patients have uncommon EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.